Borea Therapeutics has developed a gene therapy platform where viral vectors derived from adeno-associated virus (AAV) are chemically modified to strategically alter their tropism so that they target only desired cells and tissues in vivo. Our modified vectors thus operate around two key principles: increased selectivity and reduced dose requirement.

Our goal is to develop and implement new gene therapy tools to offer safe and effective therapies to patients affected by chronic or genetic disease.